About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Daily Archives: March 7, 2024
FDA Adds New AdComm to Address Genetic Metabolic Diseases
Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC). As noted in a recent posting here, … Continue reading
Posted in Advisory Committee Prepapartion
Tagged #AdCom, #AdComm, #drugapproval, #raredisease
Comments Off on FDA Adds New AdComm to Address Genetic Metabolic Diseases